Literature DB >> 1470693

Multidisciplinary treatment approach to locally advanced non-inflammatory breast cancer using chemotherapy and radiotherapy with or without surgery.

E Touboul1, J P Lefranc, J Blondon, M Ozsahin, S Mauban, L H Schwartz, M Schlienger, A Laugier, R A Guerin.   

Abstract

Between April 1982 and December 1987, 82 locally advanced non-metastatic and non-inflammatory breast cancers were treated (42 stage IIIA, 40 stage IIIB). The median follow-up is 70 months from the beginning of the treatment. The initial treatment consisted of 4 courses of chemotherapy (doxorubicin, vincristine, cyclophosphamide, 5-fluorouracil) followed by irradiation (45 Gy to the breast and nodal area). A fifth course of chemotherapy was given after radiation therapy. Three different locoregional approaches were proposed depending on the tumoral response. In 32 patients (39%) with residual tumor larger than 3 cm in diameter or located behind the nipple or with multifocal tumors, mastectomy and axillary dissection were performed. Fifty other patients (61%) benefited from conservative treatment: 32 patients (39%) achieved complete remission and received a boost to the initial tumor bed; 18 patients (22%) who had a residual mass less than or equal to 3 cm in diameter were treated by tumorectomy and axillary dissection followed by a boost to the tumorectomy site. After completion of local therapy, all patients received a sixth course of chemotherapy. A maintenance adjuvant chemotherapy regimen without anthracycline was prescribed (12 monthly cycles). Three- and 5-year disease-free survival rates were 81.7% and 72% respectively. Five-year locoregional relapse rate (with or without other sites of failure) was 8.8%. In a multivariate analysis, disease-free survival was significantly influenced by the N-stage (p < 0.0001), initial tumor size (p = 0.01), and tumor response after initial chemotherapy (p = 0.02). Five-year breast conservation probability was 58.4%.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1992        PMID: 1470693     DOI: 10.1016/0167-8140(92)90263-t

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  3 in total

1.  Pathological assessment of the response of locally advanced breast cancer to neoadjuvant chemotherapy and its implications for surgical management.

Authors:  M H El-Didi; M M Moneer; H M Khaled; S Makarem
Journal:  Surg Today       Date:  2000       Impact factor: 2.549

Review 2.  Locally advanced breast cancer in developing countries: the place of surgery.

Authors:  Justus P Apffelstaedt
Journal:  World J Surg       Date:  2003-06-06       Impact factor: 3.352

3.  Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients.

Authors:  E van der Wall; E J Rutgers; M J Holtkamp; J W Baars; J H Schornagel; J L Peterse; J H Beijnen; S Rodenhuis
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.